digital money wikipedia Knowledge

Huichuan Technology's newly established subsidiary contains a number of AI businesses. The enterprise search APP shows that Beijing Huichuan Technology Co., Ltd. was recently established with Guo Lipeng as the legal representative and a registered capital of 300 million yuan. Its business scope includes: artificial intelligence theory and algorithm software development; Basic resources and technical platform of artificial intelligence; General application system of artificial intelligence; Artificial intelligence application software development, etc. Enterprise investigation shows that the company is wholly owned by Huichuan Technology.Huaan, AVIC, etc. lined up to enter the ranks of public offering warehousing logistics REITs. According to the announcement of AVIC Fund, the AVIC Yishang warehousing logistics REITs jointly built with ESR Group, the largest new economic real estate management company in the Asia-Pacific region, are being issued. This is the first REIT issued by ESR Group in China, and its infrastructure assets consist of three warehousing and logistics parks, namely, Phase I, Phase II and Phase III of Fulaide Kunshan Logistics Park. According to the data of wind, up to now, Huaxia Fund, harvest fund, Huatai Securities Asset Management, Hongtu Innovation Fund and CICC Fund all have a listed warehousing and logistics REIT, while Huaan Waigaoqiao REIT, which was established on December 12th, has not been listed yet. In addition, Huaxia Fund and southern fund's newly declared warehousing logistics REIT are in the inquiry stage, while Huitianfu's warehousing logistics REIT is in the feedback stage.Chen Guo, China Securities: The 2025 policy will focus on expanding domestic demand and AI+ in all directions, and the Central Economic Work Conference will be held in Beijing from December 11th to 12th. Chen Guo, chief strategy officer of China Securities, said that the meeting had seven highlights, including clarifying the growth target and fiscal and monetary policy measures, expanding domestic demand in all directions as the top priority of the policy, focusing on "AI+" in science and technology, focusing on implementation of reform measures, paying attention to coping with external shocks in opening up, strengthening the expression of real estate policies, and increasing efforts to improve people's livelihood. Chen Guo said that further RRR cuts and interest rate cuts from the end of 2024 to 2025 are worth looking forward to, and the easing of the liquidity environment has become a market consensus. However, this does not mean that liquidity is rampant, because the growth of money supply in the scale of social financing still continues the requirement of matching the expected target of the overall price level of economic growth. Chen Guo believes that the 2025 policy will focus on expanding domestic demand and AI+ in an all-round way, and the strength and direction of the policy are in line with expectations. With the support of policy expectations and liquidity, it is expected that the market will continue to show the characteristics of volatility. From the perspective of investment strategy, Chen Guo suggested focusing on non-bank finance, real estate chain, consumer electronics, machinery, construction, building materials, steel, social services, catering chain and other sectors. In terms of theme, it is suggested to pay attention to investment opportunities such as "duality" and "two innovations", supply-side optimization, new quality productivity, market value management of state-owned enterprises and CSI A500 index.

Zhendong Pharmaceutical has set up a new health management service company. The enterprise search APP shows that recently, Shanxi Zhendong Health Management Service Co., Ltd. was established, with Zhao Jin as the legal representative and a registered capital of 10 million yuan. Its business scope includes: remote health management services; Health consulting services (excluding medical services), etc. Enterprise investigation shows that the company is wholly owned by Zhendong Pharmaceutical.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Consumer stocks of Hong Kong stocks fell, with Budweiser Asia Pacific (01876.HK) and China Resources Beer (00291.HK) falling more than 5%, Nongfu Spring (09633.HK) and Mengniu Dairy (02319.HK) falling 4%, and Li Ning (02331.HK) and Anta Sports (02020.HK) falling more than 3%.

The Emergency Management Department made unannounced visits to inspect enterprises involved in dust explosion. Recently, the Emergency Management Department sent a working group to carry out unannounced visits to enterprises in key industries of industry and trade in Henan and Guangxi without greeting, accompanying reception and preparing materials, so as to promote the key areas of industry and trade to do a good job in the investigation and rectification of potential safety hazards in industry and trade this winter and next spring. It was found that some enterprises involved in dust explosion did not take explosion prevention and control measures, did not set up gas lock and ash unloading devices, did not set up spark detection and elimination devices, and did not implement dust cleaning system.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.Fat Donglai is working out stricter measures to solve the problem of purchasing, including real-name purchase and regular quantitative purchase system. On December 13th, Yu Donglai issued a document saying: Fat Donglai is working out stricter and more effective measures! In the future, including real-name purchase and regular quantitative purchase system! Discuss and formulate relevant systems to control purchasing behavior and lift the membership of permanent fat east!